Trifecta Capital Advisors’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
Trifecta Capital Advisors's TXG Position: Q3 2026 in Review
Trifecta Capital Advisors reduced its 10x Genomics (TXG) stake by 87% in Q3 2026, selling an estimated $70.8K and leaving 175 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #229.
Trifecta Capital Advisors first reported a position in TXG in Q2 2025 and has held it in 6 quarters since. The position peaked at $338K in Q2 2025. 494 funds tracked by Wall St. Rank hold TXG as of Q3 2026.
- Trifecta Capital Advisors held 175 shares of 10x Genomics worth $15.8K as of Q3 2026.
- Trifecta Capital Advisors sold 1,210 10x Genomics shares in Q3 2026, an estimated $70.8K.
- 10x Genomics made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q3 2026, its #229 holding.
- Trifecta Capital Advisors first reported a position in 10x Genomics in Q2 2025 and has held it in 6 quarters since.
- Trifecta Capital Advisors's 10x Genomics position peaked at $338K in Q2 2025.
- 494 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.
Based on Trifecta Capital Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.